In the NeoSphere study5, patients with operable, locally advanced, or inflammatory HER2-positive breast cancer were randomized into 4 arms (arm A: trastuzumab and docetaxel, arm B: pertuzumab, trastuzumab, and docetaxel, arm C: pertuzumab and trastuzumab, and arm D: pertuzumab and docetaxel). Here, ERBB2 is linked to breast carcinoma.